

Index

A

- Abdominal compartment syndrome (ACS).
 - See* Intra-abdominal hypertension (IAH)
- Abdominal sepsis, IAH, 65
- Acute kidney injury (AKI)
 - biomarkers
 - Cystatin C concentrations, 85–86
 - cytosolic proteins, 84
 - human neutrophil gelatinase-associated lipocalin (NGAL), 84–85
 - interleukin 18 (IL-18), 85
 - renal epithelial enzymes, 84
 - classification, 74
 - consensus definition, infection and sepsis, 75
 - definition, 74, 75
 - diagnosis
 - creatinine clearance, 82
 - serum creatinine (SCr) levels, 82
 - serum urea concentration, 81
 - urinary biochemistry, 83
 - urine output, 82–83
 - renal endothelial and tissue damage, 80–81
 - vs.* RIFLE, definition, 74
 - septic *vs.* non-septic, 73
 - stages, 75
 - systemic and regional blood
 - flow abnormality
 - experimental models, 76–79
 - GFR, 79
 - multivariate analysis, 79
 - parameters, 80
 - sepsis induced renal failure, 76, 77
 - septic mediators, 79
- Acute lung injury (ALI). *See also* Acute respiratory distress syndrome (ARDS)
 - clinical presentation
 - clinical conditions, 105–106
 - computerized tomography, 106–107
 - prognostic factors, 107, 108
 - symptoms, 106
 - definition, 103, 104
 - GOCA scoring system, 104, 105
 - Murray score, 104, 105
 - treatment
 - fluid management, 117–118
 - management therapies, 115
 - oxygen concentration, 118
 - prone positioning, 118
 - protective lung ventilation, 116–117
- Acute respiratory distress syndrome (ARDS)
 - bronchoalveolar lavage neutrophil concentration, 113
 - clinical presentation
 - barotrauma, 107
 - clinical conditions, 105–106
 - computerized tomography, 106–107
 - prognostic factors, 107, 108
 - radiological resolution, 106, 107
 - symptoms, 106
 - clinical trials, 120–121
 - long-term patient morbidity, 120
 - mortality rate, 120
 - pathophysiology
 - diffuse alveolar damage phases, 109
 - genetic and contributing factors, 109–110
 - mechanical ventilation role, 110–115
 - pharmacologic approach
 - glucocorticoids, 119
 - inhaled nitric oxide (iNO), 119
 - inhaled prostacycline, 119–120
 - surfactants, 118–119
 - treatment
 - fluid management, 117–118
 - management therapies, 115
 - oxygen concentration, 118
 - prone positioning, 118
 - protective lung ventilation, 116–117

- ALI. *See* Acute lung injury (ALI)
- Antimicrobial agents, MRSA
- ceftaroline, 139
 - ceftobiprole, 138–139
 - dalbavancin, 139
 - daptomycin, 138
 - iclaprim, 140–141
 - linezolid, 137
 - oritavancin, 140
 - quinuprisitn/dalfoprisitin, 138
 - telavancin, 137, 140
 - tigecycline, 137–138
 - vancomycin, 134–137
- Antimicrobial dosage, MODS
- clearance (CL) measurement
 - hepatically cleared drugs, 206–207
 - hydrophilic drugs, RRT, 206
 - static and dynamic tests, 207
 - initial dosage optimization, 207–208
 - maintenance dosing
 - hepatic dysfunction, 209–213
 - renal dysfunction, 208–209
 - renal replacement therapy (RRT), 209
 - pharmacodynamics
 - definition, 202
 - interrelationship, 202, 203
 - pharmacokinetic/pharmacodynamic approach
 - concentration-dependent antimicrobials, 203
 - concentration-dependent with time-dependence, 203
 - indices, optimum activity, 203
 - interrelationship, 202, 203
 - time-dependent antimicrobials, 203
 - pharmacokinetics
 - definition, 201
 - gastrointestinal dysfunction, 204
 - hepatic dysfunction, 205
 - interrelationship, 202, 203
 - plasmatic concentration-time curve, 202
 - principal parameters, 201–202
 - renal dysfunction, 205
 - tissue hypoperfusion, 204
 - physicochemical properties
 - hydrophilic drugs, 201
 - lipophilic drugs, 201
 - water affinity, 200
 - volume of distribution (Vd) measurement
 - extracellular body water (EBW), 205, 206
 - indocyanine green (ICG) test, 206
 - sodium bromide (NaBr) test, 205
 - total body bioelectrical impedance, 206
- ARC. *See* Augmented renal clearance (ARC)
- ARDS. *See* Acute respiratory distress syndrome (ARDS)
- Augmented renal clearance (ARC)
- acute leukaemia, 183
 - burn injury, 182
 - dosing implications
 - concentration-dependant agents, 183–184
 - concentration-time-dependant agents, 185–186
 - time-dependant agents, 184–185
 - GFR measurements, 179–180
 - glomerular hyperfiltration, 180
 - haematological malignancy, 183
 - low plasma albumin concentrations, 183
 - mechanisms, 178, 179
 - neurosurgery, 182
 - prevalence, ICU, 180–181
 - trauma and surgery, 181
- B**
- β_1 -adrenergic receptor hyporesponsiveness, 93
 - B-type natriuretic peptide (BNP)
 - neutral endopeptidase 24.11, 98
 - and NT-proBNP levels, 97
 - prohormone synthesis, 96
- C**
- Cancer patients
- epidemiology, 48–49
 - hematological malignancy, 49
 - microbiology, 50
 - pathogens
 - immunosuppressive drugs and susceptibility, 51
 - Stenotrophomonas maltophilia*, 50
 - risk factors, 51–52
 - sepsis mortality predictors, 49–50
 - solid tumors, 49
- Candida species
- biofilm-producing strain activity,
 - antifungals, 161, 162
 - non-albicans species
 - shift vs., 151–152
 - variables associated, 152
 - risk factors, 152, 153
 - susceptibility, 152, 153

- Candidemia, ICU
 culture-documented candidemia, 160
 diagnosis, 156
 management
 critically ill patients, 159–160
 empirical treatment, 158
 neonatal, 164–165
 pre-emptive therapy, 158–160
 prophylaxis, 157–158
 pathogenesis, 153–154
 predictive value, *Candida*
 colonisation, 155
 risk factors, 154–155
 treatment aspects, 161
- CAP. *See* Community-acquired pneumonia (CAP)
- Cardiac function index (CFI), 96
- Cardiac troponins, 98–99
- Ceftaroline, 139
- Ceftobiprole, 138–139
- CFI. *See* Cardiac function index (CFI)
- Clinical practice guidelines
 evidence-based medicine
 AGREE collaboration, 24–25
 applicability, 28
 clarity and presentation, 28
 editorial independence, 28
 implementation, 28–29
 rigor of development, 26–27
 scope, 25
 stakeholder involvement, 25–26
 PubMed, 23
- Community-acquired pneumonia (CAP), 221
- Culture-documented candidemia, 160
- D**
- Dalbavancin, 139
- Daptomycin, 138
- Decompressive laparotomy (DL), 67
- Doppler echocardiography, 94–95
- E**
- Echocardiography, 94–95
- Empirical therapy, candidemia, 158
- Evidence-based medicine, clinical practice guidelines
 AGREE collaboration, 24–25
 applicability, 28
 clarity and presentation, 28
 editorial independence, 28
 implementation, 28–29
 rigor of development, 26–27
 scope, 25
 stakeholder involvement, 25–26
- F**
- Fas ligand, 114
- Fungi treatment
 antifungal agents
 dosages, 162
 drug selection, 162
 echinocandin compounds
 difference, 162, 163
 paediatric patients, 165
 renal/hepatic impairment, 164
 candidemia, ICU (*see* Candidemia, ICU)
 epidemiology
 Candida species, 150–153
 incidence, 150
 nosocomial fungal infections, 150
- G**
- GFR. *See* Glomerular filtration rate (GFR)
- Global end-diastolic volume (GEDV), 96
- Glomerular filtration rate (GFR), 79
- Glucocorticoids, 119
- H**
- HCAP. *See* Healthcare-acquired pneumonia (HCAP)
- Healthcare-acquired pneumonia (HCAP), 220–221
- Heat shock proteins (HSP-70), 113
- HFOV technique. *See* High frequency oscillation ventilation (HFOV) technique
- High creatinine clearance, antibacterial treatment
 augmented renal clearance, 179–180
 acute leukaemia, 183
 burn injury, 182
 dosing implications, 183–186
 haematological malignancy, 183
 low plasma albumin concentrations, 183
 neurosurgery, 182
 prevalence, ICU, 180–181
 trauma and surgery, 181
- basic pharmacological principles
 concentration vs. time curve, 172, 173

- High creatinine clearance, antibacterial treatment (*cont.*)
 pharmacodynamics (PD), 173
 pharmacokinetics (PK) parameters, 172–173
 PK-PD parameters, 173–174
 factors, bacterial eradication, 170, 171
 measurements
 Cockcroft–Gault equation, 187
 dosing strategy, 186
 TDM, 187
 pharmacokinetics-pharmacodynamics
 concentration-dependant killing, 174–175
 concentration-time-dependant killing, 176–177
 time-dependant killing, 175–176
 physiological changes, renal function effects, 177–178
- High frequency oscillation ventilation (HFOV) technique, 117
- HIV/AIDS patients
 biomarkers, 46
 C-reactive proteins, 46, 47
 epidemiology
 study characteristics, 42, 43
 survival rates, 44
 lactate dehydrogenase (LDH) levels, 47
 organ dysfunctions
 acute renal failure, 47
 hematological, 47
 neurological, 47
 respiratory, 47
 predisposing factors and characteristics
 bacteremia occurrence, 45, 46
 CD4 cell counts, 45
 HAART, 45
- I**
- IAH. *See* Intra-abdominal hypertension (IAH)
 IAIs. *See* Intra-abdominal infections (IAIs)
 Iclaprim, 140–141
 Immunocompromised patients. *See* PIRO-based approach, sepsis
 Inhaled nitric oxide (iNO), ARDS, 119
 Inhaled prostacycline, ARDS, 119–120
 Interleukin 18 (IL-18) marker, 85
 Intra-abdominal hypertension (IAH)
 abdominal sepsis, 65
 associated conditions, 61
 cardiovascular system, effects of, 63
 contributors, 61
 definition, 60
 IAP measurement, 62
 MODS stimulation, 62–64
 occurrence, 61
 severe sepsis and septic shock (*see* Severe sepsis and septic shock, IAH)
 therapeutic target
 ACS prevention, 66
 IAP reduction, 66–67
 management components, ICU, 65, 66
 paracentesis, 66
 surgical decompression, 65
 WSACS conditions, 61
- Intra-abdominal infections (IAIs)
 clinical trials, 222–223
 community acquired, 222
 treatment, 222
- L**
- Linezolid, 137
 Liquid ventilation, 117
 LODS. *See* Logistic organ dysfunction score (LODS)
 Logistic organ dysfunction score (LODS), 12–13
 Lung, multiorgan failure. *See* Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS)
- M**
- Methicillin-resistant *Staphylococcus aureus* (MRSA), gram-positive treatment
 antibiotic resistance, 130–131
 antimicrobial agents
 ceftaroline, 139
 ceftobiprole, 138–139
 dalbavancin, 139
 daptomycin, 138
 iclaprim, 140–141
 linezolid, 137
 oritavancin, 140
 quinupristin/dalfoprisitin, 138
 telavancin, 137, 140
 tigecycline, 137–138
 vancomycin, 134–137
 dosage and toxicity, 142–143
 infections, epidemiology and outcomes, 133–134
 virulence factors, 131–132
 Microcirculation resuscitation, 5

- Multorgan dysfunction syndrome (MODS).
See also Antimicrobial dosage, MODS; Intra-abdominal hypertension (IAH)
 acute renal and respiratory failure, 2
 definition, 1
 pathophysiology, 3–4
 prevention and treatment, 4–5
 scores
 admission, 18
 daily, 18
 delta, 18
 description, 9
 organ failure free days, 18
 OSF, 9, 10
 pressure-adjusted heart rate (PAR), 11
 six organ system assessment, 9–11
 vs. SOFA score, 11–12
 total maximum, 18
 sequential estimation, 8
 severity scores, 17, 18
 single acute organ failure, 1–2
 SOAP study, organ failure vs. ICU mortality rate, 2, 3
 variables type, 8, 9
- Myocardial depressant factor, 92–93
 Myocardial dysfunction monitoring.
See Sepsis-induced cardiac dysfunction; Systolic cardiac dysfunction mechanisms
- O**
- Organ system failure (OSF) score, 9, 10
 Oritavancin, 140
- P**
- PAC. *See* Pulmonary artery catheter (PAC)
 Paracentesis, 66
 Pathogens, severe sepsis
 fungi treatment
 antifungal agents, 161–164
 candidemia, ICU (*see* Candidemia, ICU)
 epidemiology, 150–153
 nosocomial fungal infections, 150
 MRSA, gram-positive treatment algorithm, suspected/proven infection, 141
 antibiotic resistance, 130–131
 antimicrobial agents, 134–141
 dosage and toxicity, 142–143
 epidemiology and outcomes, 133–134
 virulence factors, 131–132
- PiCCO system
 CFI, 96
 GEDV, 96
 pulse contour analysis, 95, 96
 transpulmonary thermodilution analysis, 95, 96
- PIRO-based approach, sepsis
 cancer patients
 epidemiology, 48–49
 pathogens, 50–52
 sepsis mortality predictors, 49–50
 HIV/AIDS patients
 epidemiology, 42–44
 infection, predisposing factors and characteristics, 45–46
 organ dysfunctions, 46–47
 methodological approach, 53
 TNM classification, 53
 utility, 52
- PIRO concept
 and clinical failure
 clinical resolution parameters, 37
 therapy optimization, 37
 ventilator-associated pneumonia (VAP) patients, 29
 goals, 34
 infection, 35–36
 organ dysfunction, 36–37
 predisposition factors, 35
 response modulation, 36
- Pneumonia
 community-acquired, 221
 healthcare-acquired, 220–221
- Positive end respiratory pressure (PEEP)
 alveoli stabilization, 111
 ARDSnet strategy, 112
 bacterial translocation, 115
 determination, ARDS management, 112
 lung injury reduction, 111
 transthoracic impedance tomography, 112
- Pre-emptive therapy, candidemia, 158–160
- Protective lung ventilation, ARDS
 conventional, 116
 extracorporeal membrane oxygenation, 117
 HFOV technique, 117
 liquid ventilation, 117
 open lung strategy, 116–117
- Pulmonary artery catheter (PAC), 95

Q

Quinuprisitin/dalfoprisitin, 138

R

Renal dysfunction assessment

AKI (*see* Acute kidney injury (AKI))

biomarkers

Cystatin C concentrations, 85–86

cytosolic proteins, 84

human neutrophil gelatinase-associated

lipocalin (NGAL), 84–85

interleukin 18 (IL-18), 85

renal epithelial enzymes, 84

definition, 74–76

limitations, 81–83

markers, renal functions

creatinine clearance, GFR

determination, 82

urine output, 82–83

pathogenesis

renal endothelial and tissue

damage, 80–81

systemic and regional blood

flow abnormality, 76–80

supra-normal renal function, 86

RIFLE

vs. AKI, definition, 74

classification, 75

criteria, 75, 76

Rivers protocol, 4

S

Sepsis and septic shock

appropriate antimicrobial therapy

antibiotic doses, 230

antimicrobial times distribution,
224–225

APACHE II score, 226

assessment, 231

clinical trials, 225–226

definition, 229–230

vs. inappropriate therapy, 226, 227

pharmacokinetic factor, 230–231

survival and antimicrobial

appropriateness, septic shock

subgroups, 225

total patient *vs.* hypotension

onset time, 231, 232

bacteremia/candidemia, 223–224

CAP, 221

choice, antimicrobial regimen, 220

HCAP, 220–221

IAIs (*see* Intra-abdominal infections
(IAIs))

inappropriate antimicrobial

administration, risk factors

antibiotic practice guidelines, 229

patients with multiresistant

organisms, 227

patients with *Pseudomonas* bacteremia,
227–228

risk reduction strategy, 228

research limitations, 229

Sepsis-induced cardiac dysfunction

detection, 94–99

BNP, 96–98

cardiac troponins, 98–99

echocardiography, 94–95

PAC, 95

PiCCO system, 95–96

diastolic, 92

systolic, mechanisms, 92–93

treatment effects, 99–100

Sequential organ failure assessment

(SOFA) score

best discriminative power, 14

maximum *vs.* ICU mortality, 16, 17

six organ dysfunction/failure, 14, 15

Severe sepsis and septic shock, IAH

causes, 64

extended empiric antibiotic therapy,
228, 229

and treatment

fluid management steps, 67–69

SOFA score. *See* Sequential organ

failure assessment (SOFA) score

Stenotrophomonas maltophilia, 50

Systolic cardiac dysfunction mechanisms

apoptosis role, 93

β_1 -adrenergic receptor hyporesponsive-
ness, 93

coronary blood flow, 93

myocardial depressant factor, 92–93

myofilament sensitivity, calcium, 93

nitric oxide (NO) role, 93

T

TDM. *See* Therapeutic drug monitoring
(TDM)

Telavancin, 137, 140

Therapeutic drug monitoring (TDM), 187

Tigecycline, 137–138

Tissue ischaemia, 81

V

Vancomycin, 134–137

Ventilator-induced lung injury (VILI)

definition, 110

Fas ligand, 114

growth-regulated oncogene (GRO), 114

and multiorgan failure, proposed

mechanisms, 110, 111

processes, 110–111

VILI. *See* Ventilator-induced lung injury (VILI)